Dr. Lencioni on Assessing Response to HCC Therapy

Video

Riccardo Lencioni, MD, professor in the department of radiology at the University of Pisa School of Medicine in Pisa, Italy, discusses how response to hepatocellular carcinoma (HCC) treatment can be best assessed in patients.

Riccardo Lencioni, MD, professor in the Department of Radiology at the University of Pisa School of Medicine in Pisa, Italy, discusses how response to hepatocellular carcinoma (HCC) treatment can be best assessed in patients.

For patients who receive locoregional therapies, there is a general consensus that using modified Response Evaluation Criteria in Solid Tumors (mRECIST) provides useful and reliable predictors of patient survival. However, there are emerging data that mRECIST criteria may also be an independent predictor of survival for patients with advanced HCC who are receiving systemic therapies.

Applying these criteria in assessing patient response to treatment will be increasingly important as the treatment landscape for HCC expands with the addition of new agents. Understanding which patients benefit most from particular therapies will be of particular value in tailoring patient care.

View more from the 2018 International Liver Cancer Association Annual Conference

Brought to you in part by Eisai

Related Videos
Patrick I. Borgen, MD
Kari Hacker, MD, PhD, NYU Grossman School of Medicine
Janos L. Tanyi, MD, PhD, associate professor, Obstetrics and Gynecology, Hospital of the University of Pennsylvania
Reshma Lillaney Mahtani, DO
Christian Marth, MD, PhD, head, professor, Department of Obstetrics and Gynecology, Innsbruck Medical University
Mansoor Raza Mirza, MD, chief oncologist, Department of Oncology, Rigshospitalet, Copenhagen University Hospital
Judy Hayek, MD, gynecologic oncology fellow, State University of New York (SUNY) Downstate College of Medicine
Leslie M. Randall, MD, MAS, professor, division head, Department of Obstetrics and Gynecology – Gynecologic Oncology, Virginia Commonwealth University School of Medicine Obstetrics and Gynecology
Dimitrios Nasioudis, MD, fellow, Gynecologic Oncology, Perelman School of Medicine, the University of Pennsylvania
Sara Corvigno, MD, PhD, translational researcher, oncology, The University of Texas MD Anderson Cancer Center